Zhao, Nan
Xie, Ran
Zhao, Xia
Zhao, Hong
Jia, Bo
Zhang, Yingjun
Luo, Lin
Huang, Zhangma
Li, Jing
Wang, Xingan
Yan, Huan
He, Bixia
Xie, Hongming
Ren, Qingyun
Cui, Yimin http://orcid.org/0000-0002-4186-1005
Funding for this research was provided by:
National Major Scientific and Technological Special Project for “Significant New Drugs Development” during the Thirteenth Five-year Plan Period (2017ZX09201006-004)
State Key Laboratory of Anti-Infective Drug Development (2015DQ780357)
Article History
First Online: 11 May 2019
Compliance with Ethical Standards
:
: This work was supported by National Major Scientific and Technological Special Project for “Significant New Drugs Development” during the Thirteenth Five-year Plan Period (No. 2017ZX09201006-004) and State Key Laboratory of Anti-Infective Drug Development (Sunshine Lake Pharma Co., Ltd), (No. 2015DQ780357).
: Yingjun Zhang, Lin Luo, Zhangma Huang, Jing Li, Xingan Wang, Huan Yan, Bixia He, Hongming Xie and Qingyun Ren are employees of Sunshine Lake Pharma Co., Ltd.
: All procedures performed in the trials involving human participants were in accordance with the Declaration of Helsinki and followed the principles of Good Clinical Practice. The protocol and informed consent documentation were reviewed and approved by Peking University First Hospital Ethical Committee (Peking, China).
: Informed consent was obtained from all individual subjects included in the trial.